Joan Carles - Publications, H-index & Citations

Joan Carles

vall d′hebron institute of oncology (vhio)

55H指数

716论文数

2.0W被引数

收录论文 144

发表时间

Corrigendum to Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study [European Journal of Cancer Volume 213, December 2024, 115078]勘误：Talazoparib 联合 enzalutamide 治疗 metastatic castration-resistant prostate cancer 的安全性分析，来自随机、安慰剂对照、III 期 TALAPRO-2 研究的结果 [European Journal of Cancer Volume 213, December 2024, 115078]

European Journal of Cancer

IF7.1

2025-11-13

PREAI

Arun A. Azad; Karim Fizazi; Nobuaki Matsubara; Fred Saad; Ugo De Giorgi; Jae Young Joung; Peter C.C. Fong; Robert J. Jones; Stefanie Zschäbitz; Jan Oldenburg; Neal D. Shore; Curtis Dunshee; Joan Carles; Andre P. Fay; Xun Lin; Liza DeAnnuntis; Nicola Di Santo; Michael A. Zielinski; Neeraj Agarwal

Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors 基因组可操作性及匹配的靶向疗法在为期十年的机构实体瘤精准医学项目中的应用

ESMO Open

IF8.3

2025-11-06

OAAI

R. Dienstmann; A. Vivancos; P. Nuciforo; S. Aguilar; F. Ruiz-Pace; C. Viaplana; J. Gonzalez; B. Fite; A. Pedrola; E. Elez; C. Saura; E. Felip; T. Macarulla; J. Capdevila; L. Fariñas-Madrid; J. Carles; J. Mateo; E. Muñoz-Cosuelo; J. Balmaña; I. Braña; E. Garralda; J. Tabernero

European Urology Oncology

IF9.3

2025-11-04

OAAI

Joan Carles; Bertrand Tombal; Maha Hussain; Fred Saad; Karim Fizazi; Álvaro Montesa Pino; Maria José Méndez-Vidal; Alejo Rodriguez-Vida; Daniel Castellano; Pablo Borrega; Patrick Adorjan; Cristina Moretones; Manjari Dissanayake; Matthew R. Smith

Balancing risks and benefits of immune checkpoint inhibitors in patients with pre-existing immune-mediated inflammatory diseases: A comprehensive review 权衡免疫检查点抑制剂在存在基础免疫介导性炎症性疾病患者中的风险与获益：一项综合综述

Critical Reviews in Oncology/Hematology

IF0

2025-10-30

PREAI

Clara Salva de Torres; Ernesto Trallero-Araguas; David Marmolejo; José Maria Ucha Hermida; Nely Díaz Mejía; Pau Mascaró Baselga; Abraham André Arturo Geng-Cahuayme; Laia Catalan; Macarena González; Rafael Morales-Barrera; Joan Carles; Enrique Gallardo; Cristina Suárez

Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial Talazoparib 联合 enzalutamide 治疗 metastatic castration-resistant prostate cancer 男性患者的最终总生存结果：来自随机、安慰剂对照、III期 TALAPRO-2 试验的数据

lancet

IF0

2025-07-16

PREAI

Neeraj Agarwal; Arun A Azad; Joan Carles; André P Fay; Nobuaki Matsubara; Cezary Szczylik; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Fred Saad; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Xun Lin; Cynthia G Healy; Matko Kalac; Dana Kennedy; Karim Fizazi

Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial Talazoparib 联合 enzalutamide 治疗 HRR 缺陷型转移性去势抵抗性前列腺癌的男性患者：来自随机、安慰剂对照的 III 期 TALAPRO-2 试验的最终总生存结果

lancet

IF0

2025-07-16

PREAI

Karim Fizazi; Arun A Azad; Nobuaki Matsubara; Joan Carles; André P Fay; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Dingwei Ye; Xun Lin; Matko Kalac; A Douglas Laird; Dana Kennedy; Neeraj Agarwal

Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial 卡博替尼联合阿替利珠单抗在转移性前列腺癌中的研究（CONTACT-02）：一项III期、开放标签、随机试验的最终分析

lancet oncology

IF0

2025-06-13

PREAI

Neeraj Agarwal; Arun A Azad; Joan Carles; Nobuaki Matsubara; Stéphane Oudard; Fred Saad; Axel S Merseburger; Andrey Soares; Bradley A McGregor; Bogdan Zurawski; Marinos Tsiatas; Scott North; Igor Bondarenko; Margarita Alfie; Evangelos Bournakis; Lorenzo Antonuzzo; Lena Evilevitch; Andrew Simmons; Fong Wang; Roberta Ferraldeschi; Prachi Nandoskar; Sumanta K Pal

Corrigendum to “Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients” [Eur. Urol. Oncol. 7 (2024) 954–964]勘误：关于“基于RB1、PTEN和TP53在转移性激素敏感性前列腺癌患者中开发并独立验证预后基因表达签名”[Eur. Urol. Oncol. 7 (2024) 954–964]

European Urology Oncology

IF9.3

2025-05-01

PREAI

Natalia Jiménez; Marta Garcia de Herreros; Òscar Reig; Mercedes Marín-Aguilera; Caterina Aversa; Laura Ferrer-Mileo; Samuel García-Esteve; Leonardo Rodríguez-Carunchio; Isabel Trias; Albert Font; Alejo Rodriguez-Vida; Miguel Ángel Climent; Sara Cros; Isabel Chirivella; Montserrat Domènech; Mariona Figols; Joan Carles; Cristina Suárez; Daniel Herrero Rivera; Enrique González-Billalabeitia; Claudia Cívico; Núria Sala-González; Vicenç Ruiz de Porras; Maria J. Ribal; Aleix Prat; Begoña Mellado

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study Talazoparib联合enzalutamide治疗转移性去势抵抗性前列腺癌: 来自随机，安慰剂对照，III期TALAPRO-2研究的安全性分析

EUROPEAN JOURNAL OF CANCER

IF7.1

2024-12-01

OAAI

Azad, Arun A.; Fizazi, Karim; Matsubara, Nobuaki; Saad, Fred; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Jones, Robert J.; Zschaebitz, Stefanie; Oldenburg, Jan; Shore, Neal D.; Dunshee, Curtis; Carles, Joan; Fay, Andre P.; Lin, Xun; Deannuntis, Liza; Di Santo, Nicola; Zielinski, Michael A.; Agarwal, Neeraj

Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer 转移性去势抵抗性前列腺癌患者的镭223加恩扎鲁他胺强化治疗

FRONTIERS IN MEDICINE

IF3

2024-10-24

OAAI

Shore, Neal; Carles, Joan; McDermott, Ray; Agarwal, Neeraj; Tombal, Bertrand

Five latent factors underlie response to immunotherapy 免疫疗法反应的五个潜在因素

NATURE GENETICS

IF31.8

2024-09-12

OAAI

Usset, Joseph; Huber, Axel Rosendahl; Andrianova, Maria A.; Batlle, Eduard; Carles, Joan; Cuppen, Edwin; Elez, Elena; Felip, Enriqueta; Gomez-Rey, Marina; Lo Giacco, Deborah; Martinez-Jimenez, Francisco; Munoz-Couselo, Eva; Siu, Lillian L.; Tabernero, Josep; Vivancos, Ana; Muinos, Ferran; Gonzalez-Perez, Abel; Lopez-Bigas, Nuria

Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial 全身磁共振成像作为去势抵抗性前列腺癌骨转移的治疗反应生物标志物: iPROMET临床试验

EUROPEAN UROLOGY

IF25.2

2024-09-01

PREAI

Garcia-Ruiz, Alonso; Macarro, Carlos; Zacchi, Francesca; Morales-Barrera, Rafael; Grussu, Francesco; Casanova-Salas, Irene; Sanguedolce, Francesco; Gonzalez, Macarena; Cresta-Morgado, Pablo; de Albert, Matias; Garcia-Bennett, Josep; Marmolejo, David; Planas, Jacques; Roche, Sarai; Mast, Richard; Zatse, Christina; Piulats, Josep M.; Herrera-Imbroda, Bernardo; Regis, Lucas; Agundez, Laura; Olmos, David; Calvo, Nahum; Escobar, Manuel; Carles, Joan; Mateo, Joaquin; Perez-Lopez, Raquel

Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients

EUROPEAN UROLOGY ONCOLOGY

IF9.3

2024-08-01

OAAI

Jimenez, Natalia; de Herreros, Marta Garcia; Reig, Oscar; Marin-Aguilera, Mercedes; Aversa, Caterina; Ferrer-Mileo, Laura; Garcia-Esteve, Samuel; Rodriguez-Carunchio, Leonardo; Trias, Isabel; Font, Albert; Rodriguez-Vida, Alejo; Climent, Miguel Angel; Cros, Sara; Chirivella, Isabel; Domenech, Montserrat; Figols, Mariona; Carles, Joan; Suarez, Cristina; Rivera, Daniel Herrero; Gonzalez-Billalabeitia, Enrique; Civico, Claudia; Sala-Gonzalez, Nuria; de Porras, Vicenc Ruiz; Ribal, Maria J.; Prat, Aleix; Mellado, Begona

Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer TALAPRO-2研究结果的简明语言摘要: 塔拉唑帕利加恩扎鲁他胺与安慰剂加恩扎鲁他胺治疗晚期前列腺癌的比较

FUTURE ONCOLOGY

IF2.6

2024-07-12

OAAI

Agarwal, Neeraj; Azad, Arun A.; Carles, Joan; Fay, Andre P.; Matsubara, Nobuaki; Heinrich, Daniel; Szczylik, Cezary; Giorgi, Ugo De; Joung, Jae Young; Fong, Peter C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschabitz, Stefanie; Oldenburg, Jan; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Zohren, Fabian; Fizazi, Karim

TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Piulats, Josep M.; Azad, Arun A.; Laird, A. Douglas; Matsubara, Nobuaki; Fizazi, Karim; Shore, Neal D.; Karsh, Lawrence; Liu, Glenn; Fay, Andre P.; Carles, Joan; Jones, Robert J.; Voog, Eric; Zschabitz, Stefanie; De Giorgi, Ugo; Yip, Steven M.; Mu, Xinmeng Jasmine; Lin, Xun; Engelsberg, Arne; Agarwal, Neeraj

Identification of a novel agnostic predictive multiomic signature via Elastic Net/Machine Learning in TALAPRO-2 ( TP-2), a phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Liu, Glenn; Mu, Xinmeng Jasmine; Fizazi, Karim; Laird, A. Douglas; Matsubara, Nobuaki; Yip, Steven M.; Pu, Jie; Carles, Joan; Fay, Andre P.; Jones, Robert J.; Zschaebitz, Stefanie; Piulats, Josep M.; Joung, Jae Young; Roh, Whijae; Chelliserry, Jijumon; Di Santo, Nicola; Saul, Michelle; Azad, Arun A.; Agarwal, Neeraj

Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient 病例报告: 转移性去势抵抗性前列腺癌患者对镭223和雄激素阻断治疗的异常和持久反应

FRONTIERS IN ONCOLOGY

IF3.3

2024-03-08

OAAI

Zacchi, Francesca; Carles, Joan; Gonzalez, Macarena; Maldonado, Xavier; Perez-Lopez, Raquel; Semidey, Maria Eugenia; Mateo, Joaquin

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial (vol 30, pg 257, 2024)一线talazoparib联合恩扎鲁他胺治疗HRR缺乏的转移性去势抵抗性前列腺癌: 3期TALAPRO-2试验 (第30卷，257页，2024页)

NATURE MEDICINE

IF50

2024-01-31

OAAI

Fizazi, Karim; Azad, Arun A.; Matsubara, Nobuaki; Carles, Joan; Fay, Andre P.; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschabitz, Stefanie; Oldenburg, Jan; Ye, Dingwei; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Laird, A. Douglas; Zohren, Fabian; Agarwal, Neeraj

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial 一线talazoparib联合恩扎鲁他胺治疗HRR缺乏的转移性去势抵抗性前列腺癌: 3期TALAPRO-2试验

NATURE MEDICINE

IF50

2023-12-04

OAAI

Fizazi, Karim; Azad, Arun A.; Matsubara, Nobuaki; Carles, Joan; Fay, Andre P.; De Giorgi, Ugo; Joung, Jae Young; Fong, Peter C. C.; Voog, Eric; Jones, Robert J.; Shore, Neal D.; Dunshee, Curtis; Zschaebitz, Stefanie; Oldenburg, Jan; Ye, Dingwei; Lin, Xun; Healy, Cynthia G.; Di Santo, Nicola; Laird, A. Douglas; Zohren, Fabian; Agarwal, Neeraj

Long-term survival upon anti-PD-(L)1 monotherapy in metastatic urothelial cancer (mUC): A multicenter retrospective study

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Stockem, C. F.; Einerhand, S.; Miras Rodriguez, I.; Perez Valderrama, B.; Vulsteke, C.; De Meulenaere, A. M.; Barrera, R. Morales; Carles Galceran, J.; Giannatempo, P.; Rametta, A.; Bottelli, A.; Lefort, F.; Bakaloudi, D. R.; Talukder, R.; Grivas, P.; van der Heijden, M. S.

研究方向